Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
- PMID: 32963908
- PMCID: PMC7500742
- DOI: 10.7759/cureus.9867
Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
Abstract
Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the important considerations in the evaluation and management of this rare syndrome. HILS should be considered in the differential diagnosis for cardiac tamponade of otherwise unclear etiology in patients taking 100 mg daily or more of hydralazine for longer than three months. A temporal association between the offending drug and presenting symptoms, resolution of symptoms upon discontinuation, and a positive anti-histone antibody test can all support the diagnosis of this syndrome.
Keywords: drug-induced lupus (dil); hydralazine-induced lupus syndrome; pericardial effusion.
Copyright © 2020, Wilson et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
A Case of Seronegative ANA Hydralazine-Induced Lupus Presenting With Pericardial Effusion and Pleural Effusion.Cureus. 2020 Aug 18;12(8):e9831. doi: 10.7759/cureus.9831. Cureus. 2020. PMID: 32953340 Free PMC article.
-
Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.Case Rep Rheumatol. 2017;2017:5245904. doi: 10.1155/2017/5245904. Epub 2017 Jan 17. Case Rep Rheumatol. 2017. PMID: 28194293 Free PMC article.
-
Antinuclear antibody-negative lupus? An ominous presentation of hydralazine-induced lupus syndrome.Eur J Rheumatol. 2018 Dec;5(4):272-274. doi: 10.5152/eurjrheum.2018.18040. Epub 2018 Jun 20. Eur J Rheumatol. 2018. PMID: 30071945 Free PMC article.
-
Drug-induced lupus erythematosus.Arch Dermatol Res. 2009 Jan;301(1):99-105. doi: 10.1007/s00403-008-0895-5. Epub 2008 Sep 17. Arch Dermatol Res. 2009. PMID: 18797892 Review.
-
Drug-induced systemic lupus erythematosus.Clin Pharm. 1985 Nov-Dec;4(6):657-63. Clin Pharm. 1985. PMID: 2866863 Review.
Cited by
-
Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.BMC Pharmacol Toxicol. 2025 Feb 7;26(1):27. doi: 10.1186/s40360-025-00867-6. BMC Pharmacol Toxicol. 2025. PMID: 39920868 Free PMC article.
References
-
- Drug-induced lupus. Borchers AT, Keen CL, Gershwin ME. Ann N Y Acad Sci. 2007;1108:166–182. - PubMed
-
- Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus-syndrome. Carey RM, Coleman M, Feder A. Am J Med. 1973;54:84–87. - PubMed
-
- Cardiac tamponade in hydralazine-induced systemic lupus erythematosus. Aylward PE, Tonkin AM, Bune A. Aust N Z J Med. 1982;12:546–547. - PubMed
-
- Cardiac tamponade, associated with hydralazine therapy, in a patient with rapid acetylator status. Anandadas JA, Simpson P. https://pubmed.ncbi.nlm.nih.gov/3741750/ Br J Clin Pract. 1986;40:305–306. - PubMed
Publication types
LinkOut - more resources
Full Text Sources